Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry

Seminars in Arthritis and Rheumatism

Volumn 46, Issue 2, 2016, Pages 200-208

  Tolosa Vilella, Carles ^a   Morera Morales, Maria Lluisa ^a   Simeón Aznar, Carmen Pilar ^b   Marí Alfonso, Begoña ^a   Colunga Arguelles, Dolores ^c   Callejas Rubio, José Luis ^d   Rubio Rivas, Manuel ^e   Freire Dapena, Maika ^f   Guillén del Castillo, Alfredo ^b   Iniesta Arandia, Nerea ^g   Castillo Palma, Maria Jesús ^h   Egurbide Arberas, Marivi ⁱ   Trapiellla Martínez, Luis ^j   Vargas Hitos, José A ^k   Todolí Parra, José Antonio ^l   Rodriguez Carballeira, Mónica ^e   Marin Ballvé, Adela ^m   Pla Salas, Xavier ⁿ   Rios Blanco, Juan José ^o   Fonollosa Pla, Vicent ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ HOSPITAL DE CRUCES   (Spain)

^j HOSPITAL DE CABUEÑES   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^l HOSPITAL UNIVERSITARIO LA FE   (Spain)

^m HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

ⁿ Unit of Systemic Autoimmune Diseases   (Spain)

^o HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

more..

Author keywords

Anti centromere antibodies; Anti topoisomerase I antibodies; Diffuse cutaneous SSc; Digital ulcers; Limited cutaneous SSc; Nailfold capillaroscopy; SSc sine scleroderma; Survival; Systemic sclerosis

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN DERIVATIVE;

ACROOSTEOLYSIS; ADULT; AGE; ARTICLE; AUTOIMMUNITY; CAPILLAROSCOPY; CAUSE OF DEATH; CLINICAL FEATURE; DEMOGRAPHY; DIFFUSE SCLERODERMA; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FINGER ULCER; HEALTH CARE FACILITY; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; LIMITED SCLERODERMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SKIN CALCIFICATION; SPAIN; SURVIVAL RATE; SYSTEMIC SCLEROSIS; TELANGIECTASIA; UNIVARIATE ANALYSIS; AGED; ANGIOSCOPY; COMPLICATION; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; PATHOPHYSIOLOGY; REGISTER; SKIN ULCER;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MICROSCOPIC ANGIOSCOPY; MIDDLE AGED; REGISTRIES; SCLERODERMA, SYSTEMIC; SKIN ULCER; SPAIN; SURVIVAL RATE;

EID: 84992080176     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2016.04.007     Document Type: Article

References (39)

1. [1] Gabrielli, A., Avvedimento, E.V., Krieg, T., Scleroderma. N Engl J Med 360 (2009), 1989–2003.
2. [2] Kayser, C., Fritzler, M.J., Autoantibodies in systemic sclerosis: unanswered questions. Front Immunol, 6, 2015, 167.
3. [3] Matucci-Cerinic, M., Kahaleh, B., Wigley, F.M., Evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 65 (2013), 1953–1962.
4. [4] Tolosa-Vilella, C., Simeón-Aznar, C.P., Gabarró, L., Raynaud's phenomenon. Med Clin 132 (2009), 712–718.
5. [5] Hachulla, E., Clerson, P., Launay, D., Lambert, M., Morell-Dubois, S., Queyrel, V., et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 34 (2007), 2423–2430.
6. [6] Bruni, C., Guiducci, S., Bellando-Randone, S., Lepri, G., Braschi, F., Fiori, G., et al. Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. Rheumatology 54 (2015), 72–76.
7. [7] Baron, M., Chung, L., Gyger, G., Hummers, L., Khanna, D., Mayes, M.D., et al. Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. Clin Rheumatol 33 (2014), 207–214.
8. [8] Simeón-Aznar, C.P., Fonollosa-Plá, V., Tolosa-Vilella, C., Espinosa-Garriga, G., Ramos-Casals, M., Campillo-Grau, M., et al. Registry of the Spanish Network for Systemic Sclerosis: clinical pattern according to cutaneous subsets and immunological status. Sem Arthritis Rheum 41 (2012), 789–800.
9. [9] Mouthon, I., Mestre-Stanislas, C., Bérezné, A., Rannou, F., Guilpain, P., Revel, M., et al. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis 69 (2010), 214–217.
10. [10] Mihai, C., Landewé, R., van der Heijde, D., Walker, U.A., Constantin, P.I., Gherghe, A.M., et al. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis, 2015, 10.1136/annrheumdis-2014-205897.
11. [11] LeRoy, B.C., Medsger, T.A. Jr, Criteria for the classification of early systemic sclerosis. J Rheumatol 28 (2001), 1573–1576.
12. [12] Simeón-Aznar, C.P., Tolosa-Vilella, C., Gabarró-Juliá, L., Campillo-Grau, M., Guillén del Castillo, A., Fonollosa-Plá, V., et al. Systemic sclerosis sine scleroderma and limited cutaneous systemic sclerosis: similarities and differences. Clin Exp Rheumatol 32:6 Suppl. 86 (2014), S33–S40.
13. [13] Poormoghim, H., Lucas, M., Fertig, N., Medsger, T.A. Jr, Systemic sclerosis sine scleroderma: demographic, clinical and serologic features and survival in forty-eight patients. Arthritis Rheum 43 (2000), 444–451.
14. [14] No authors listed, Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23 (1980), 581–590.
15. [15] van den Hoogen, F., Khanna, D., Fransen, J., Johnson, S.R., Baron, M., Tyndall, A., et al. classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65 (2013), 2737–2747.
16. [16] Simeon, C.P., Armadans, L., Fonollosa, V., Solans, R., Selva, A., Villar, M., et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 42 (2003), 71–75.
17. [17] Hoeper, M.M., Bogaard, H.J., Condliffe, R., Frantz, R., Khanna, D., Kurzyna, M., et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62:Suppl. (2013), D42–D50.
18. [18] Coghlan, J.G., Denton, C.P., Grunig, E., Bonderman, D., Distler, O., Khanna, D., et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73 (2014), 1340–1349.
19. [19] Traub, Y.M., Shapiro, A.P., Rodnan, G.P., Medsger, T.A., McDonald, R.H. Jr, Steen, V.D., et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) 62 (1983), 335–352.
20. [20] Maricq, H.R., Spencer-Green, G., LeRoy, E.C., Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis. Am J Med. 61 (1976), 862–870.
21. [21] Sunderkötter, C., Herrgott, I., Bruckner, C., Moinzadeh, P., Pfeiffer, C., Gerss, J., et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 160 (2009), 835–843.
22. [22] Tiev, K.P., Diot, E., Clerson, P., Dupuis-Simeon, F., Hachulla, E., Hatron, P.Y., et al. Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinérAIR-Sclérodermie). J Rheumatol 36 (2009), 1470–1476.
23. [23] Ferri, C., Valentini, G., Cozzi, F., Sebastiani, M., Michelassi, C., LaMontagna, G., et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine 81 (2002), 139–153.
24. [24] Xu, D., Li, M.T., Hou, Y., Wang, Q., Hu, C.J., Song, N., et al. Clinical characteristics of systemic sclerosis patients with digital ulcers in China. Clin Exp Rheumatol 31:2 Suppl. 76 (2013), 46–49.
25. [25] Castellví, I., Simeón-Aznar, C.P., Sarmiento, M., Fortuna, A., Mayos, M., Geli, C., et al. Association between nailfold capillaroscopy findings and pulmonary function tests in patients with systemic sclerosis. J Rheumatol 42 (2015), 222–227.
26. [26] Sebastiani, M., Manfredi, A., Vukatana, G., Moscatelli, S., Riato, L., Bocci, M., et al. Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study. Ann Rheum Dis 71 (2012), 67–70.
27. [27] Walker, U.A., Tyndall, A., Czirjak, L., Denton, C., Farge-Bancel, D., Kowal-Bielecka, O., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 66 (2007), 754–763.
28. [28] Denton, C.P., Krieg, T., Guillevin, L., Schwierin, B., Rosenberg, D., Silkey, M., et al. Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. Ann Rheum Dis 71 (2012), 718–721.
29. [29] Korn, J.H., Mayes, M., Matucci Cerinic, M., Rainisio, M., Pope, J., Hachulla, E., et al. for the RAPIDS-1 Study Group. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50 (2004), 3985–3993.
30. [30] Khimdas, S., Harding, S., Bonner, A., Zummer, B., Baron, M., Pope, J., et al. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry. Arthritis Care Res 63 (2011), 142–149.
31. [31] Hofstee, H.M., Noordegraaf, A.V., Voskuyl, A.E., Dijkmans, B.A., Postmus, P.E., Smulders, Y.M., et al. Nailfold capillary density isassociated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis. Ann Rheum Dis 68 (2009), 191–195.
32. [32] Ong, Y.Y., Nikoloutsopoulos, T., Bond, C.P., Smith, M.D., Ahern, M.J., Roberts-Thomson, P.J., Decreased nailfold capillary density in limited scleroderma with pulmonary hypertension. Asian Pac J Allergy Immunol 16 (1998), 81–86.
33. [33] Romaniello, A., Viola, G., Salsano, F., Rosato, E., In systemic sclerosis patients, Bosentan is safe and effective for digital ulcer prevention and it seems to attenuate the development of pulmonary arterial hypertension. Rheumatology (Oxford) 53 (2014), 570–571.
34. [34] Avouac, J., Guerini, H., Wipff, J., Assous, N., Chevrot, A., Kahan, A., et al. Radiological hand involvement in systemic sclerosis. Ann Rheum Dis 65 (2006), 1088–1092.
35. [35] Nihtyanova, S.I., Brough, G.M., Black, C.M., Denton, C.P., Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 67 (2008), 120–123.
36. [36] Cutolo, M., Smith, V., State of the art on nailfold capillaroscopy: a reliable diagnostic tool and putative biomarker in rheumatology?. Rheumatology (Oxford) 52 (2013), 1933–1940.
37. [37] Morrisroe, K.B., Stevens, W., Nandurkar, H., Prior, D., Thakkar, V., Roddy, J., et al. The association of antiphospholipid antibodies with cardiopulmonary manifestations of systemic sclerosis. Clin Exp Rheumatol 32:6 Suppl. 86 (2014), S133–S137.
38. [38] Rubio-Rivas, M., Royo, C., Simeón, C.P., Corbella, X., Fonollosa, V., Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Sem Arthritis Rheum 44 (2014), 208–219.
39. [39] Vettori, S., Cuomo, G., Abignano, G., Iudici, M., Valentini, G., Survival and death causes in 251 systemic sclerosis patients from a single Italian center. Reumatismo 62 (2010), 202–209.